Over 220,000 Patients in the World Benefited from Heberprot-P

Havana, Cuba, Apr 12 (acn) – More than 220,000 patients in 30 countries benefit from the use of the Cuban medicine Heberprot-P, unique of its kind and marketed by Cuba, which reduces the rate of diabetic foot amputation.

The benefits and impact that Heberprot-P causes internationally contribute to the increase of interest, according to data provided to Radio Rebelde by Raudel Sosa, promoter of the Center for Genetic Engineering and Biotechnology in Havana.

“Even U.S. President Barak Obama during his recent visit took an interest in the drug’s benefits, he said, and we make incursions not only into countries where we have historically had relations in Latin America, such as Venezuela and Ecuador”.

“We registered Heberprot-P in Russia, he commented, and in the Arab countries and have results in Kuwait. Interest increases day after day because people know about its advantages.”

In Cuba, the number of persons benefited amounts to 50,000, with unprecedented impact, and amputation decreases below 20 percent. Primary health care is essential – it’s closer to communities, from family doctor offices and polyclinics.

The Center for Genetic Engineering and Biotechnology (CIGB) in Havana designed the drug. There, the medicament that encourages healing, sold in glass bulbs for injection, is produced and marketed.